You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline Snapshot as of July 31, 2018

  • Discovery Projects
  • Phase 1
    15
  • Phase 2
    6
  • Phase 3
    17
  • Registration
    5
  • Total43
 
Compound Name
Indication
Phase
Submission Typesort descending
Compound Type
dacomitinib (PF-00299804)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
pan-HER Inhibitor
Go to clinical trial
1st Line EGFR-activating mutant Non-Small Cell Lung Cancer (ORPHAN - U.S., PRIORITY REVIEW) Registration New Molecular Entity Small Molecule
gedatolisib (PF-05212384)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Phosphatidyl inositol-3 kinase catalytic sub-unit a inhibitor / mammalian target of rapamycin inhibitor (PI3K/mTOR)
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
glasdegib (PF-04449913)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/ low-dose cytarabine (LDAC) for: Acute Myeloid Leukemia (PRIORITY REVIEW)
Project advanced
Registration New Molecular Entity Small Molecule
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
2nd Line ALK Non-Small Cell Lung Cancer (BREAKTHROUGH, ORPHAN - U.S., PRIORITY REVIEW) Registration New Molecular Entity Small Molecule
PF-04518600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
OX40 receptor Agonist
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06671008
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
cadherin 3, type 1, P-cadherin (placental) (CDH3)
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06688992
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Antibody Drug Conjugate
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06801591
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Cancer Immunotherapy (Biologic) Phase 1 New Molecular Entity Biologic
PF-06804103
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Antibody Drug Conjugate
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
EZH2 inhibitor
Go to clinical trial
Cancer
Project advanced
Phase 1 New Molecular Entity Small Molecule
PF-06863135
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Bispecific protein
Go to clinical trial
Multiple Myeloma (Biologic) Phase 1 New Molecular Entity Biologic
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
CDK inhibitor
Go to clinical trial
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
talazoparib (MDV3800)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Germline BRCA Mutated Metastatic Breast Cancer (PRIORITY REVIEW)
Project advanced
Registration New Molecular Entity Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Merkel Cell Carcinoma (E.U.) (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Combo w/ PF-04518600 (OX40) for: Squamous Cell Carcinoma of the Head and Neck (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Combo w/ PF-05082566 (4-1BB) for: Melanoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Triple-Negative Breast Cancer (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Combo w/ PF-04518600 (OX40) and PF-05082566 (4-1BB) for: Cancer (Biologic) Phase 1 Product Enhancement Biologic
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options